

PTO/SB/08a (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Project of 1995, respondents are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/636,088        |
| Filing Date            | 08/07/2003        |
| First Named Inventor   | Frank HIMMELSBACH |
| Art Unit               | 1616              |
| Examiner Name          |                   |
| Attorney Docket Number | 1/1386            |

### U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| MB                 |                       | US- 2003/105077 A1  | 06/05/2003                     | Kanstrup, A. B. et al                              |   |
| MB                 |                       | US- 2003/199528 A1  | 10/23/2003                     | Kanstrup, A. B. et al                              |   |
| MB                 |                       | US- 2003/236272 A1  | 12/25/2003                     | Carr, R. D.  |   |
| MB                 |                       | US- 2002/161001 A1  | 10/31/2002                     | Kanstrup, A. B. et al                              |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| MB                 |                       | WO 02/068420 A1  | 09/06/2002                     | BI Pharma KG                                       |   |                |
| MB                 |                       | WO 03/057200 A2  | 07/17/2003                     | Novo Nordisk A/S                                   |   |                |
| MB                 |                       | EP 1 338 595 A2  | 08/27/2003                     | Eisai Co., Ltd.                                    |   |                |
|                    |                       |  |                                |  |   |                |
|                    |                       |  |                                |  |   |                |
|                    |                       |  |                                |  |   |                |
|                    |                       |  |                                |  |   |                |

Examiner  
Signature

*Mark Buer*


Date  
Considered

5/30/06 6/13/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/636,088        |
| Filing Date            | 08/07/2003        |
| First Named Inventor   | Frank HIMMELSBACH |
| Art Unit               | 1616              |
| Examiner Name          |                   |
| Attorney Docket Number | 1/1386            |

**U. S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| AM                 |                       | US- 2002/0198205  | 12/26/2002                     | Himmelsbach, F. et al                              |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |
|                    |                       | US-   |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| MB                 |                       | WO 03/004496 A1  | 01/16/2003                     | Novo Nordisk A/S                                   |   |                |
|                    |                       | WO 02/02560 A2   | 01/10/2002                     | Novo Nordisk A/S                                   |   |                |
|                    |                       | WO 03/024965 A2  | 03/27/2003                     | Novo Nordisk A/S                                   |   |                |

Examiner  
SignatureDate  
Considered

6/3/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.